JP2018515145A - 初期アルツハイマー病又は軽度認知障害の診断方法 - Google Patents
初期アルツハイマー病又は軽度認知障害の診断方法 Download PDFInfo
- Publication number
- JP2018515145A JP2018515145A JP2018513247A JP2018513247A JP2018515145A JP 2018515145 A JP2018515145 A JP 2018515145A JP 2018513247 A JP2018513247 A JP 2018513247A JP 2018513247 A JP2018513247 A JP 2018513247A JP 2018515145 A JP2018515145 A JP 2018515145A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- alzheimer
- cognitive impairment
- mild cognitive
- diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 95
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 70
- 208000027061 mild cognitive impairment Diseases 0.000 title claims abstract description 61
- 238000003745 diagnosis Methods 0.000 title claims abstract description 46
- 108091063796 miR-206 stem-loop Proteins 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 48
- 239000000523 sample Substances 0.000 claims description 41
- 210000001519 tissue Anatomy 0.000 claims description 26
- 238000004458 analytical method Methods 0.000 claims description 25
- 102100034343 Integrase Human genes 0.000 claims description 16
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 210000001706 olfactory mucosa Anatomy 0.000 claims description 15
- 230000000692 anti-sense effect Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 238000004393 prognosis Methods 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 238000005259 measurement Methods 0.000 claims description 8
- 230000002860 competitive effect Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000000018 DNA microarray Methods 0.000 claims description 5
- 238000000636 Northern blotting Methods 0.000 claims description 5
- 102000006382 Ribonucleases Human genes 0.000 claims description 5
- 108010083644 Ribonucleases Proteins 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 12
- 238000010562 histological examination Methods 0.000 abstract description 3
- 206010012289 Dementia Diseases 0.000 description 12
- 230000003920 cognitive function Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 208000028698 Cognitive impairment Diseases 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 238000013399 early diagnosis Methods 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 108091070501 miRNA Proteins 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 102000013498 tau Proteins Human genes 0.000 description 3
- 108010026424 tau Proteins Proteins 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 206010034719 Personality change Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 210000000492 nasalseptum Anatomy 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000007436 olfactory function Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229940124717 Alzheimer's therapeutics Drugs 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Abstract
Description
更にまた、本発明において、前記嗅覚組織試料は、嗅覚粘膜試料又は嗅覚上皮試料であることを特徴とする。
また、標準対象体は、当業者にとって周知の方法に従い、アルツハイマー病の特異的な段階を有する他の定義によっても分類可能である。
上述した方法に従い、基準レベル以上の試料に対してはアルツハイマー病の発病率が高いことを予測する。
ソウル大学病院臨床試験審査委員会により承認された研究プロトコールを用いて、患者から同意を得た後に実験を行った。50歳以上の被験者がこの研究に参加した。認知障害を有する患者はソウル大学病院神経科の外来患者クリニックから募集し、一般的な認知機能を有する参加者は募集公告を出して募集した。認知機能を評価するために、全ての患者は韓国版の臨床的認知症尺度(clinical dementia rating;CDR)検査、簡易精神状態検査(Mini−Mental State Examination;MMSE−K)及びアルツハイマー病評価尺度認知機能下位尺度(Alzheimer’s Disease Assessment Scale−cognitivesubscale;ADAS−cog−K)検査を受けた。Beck憂うつ尺度II(Beck Depression Inventory−II;BDI−II)は、憂うつ症に随伴する認知の損傷を決定するために全ての患者に対して行われた。軽症から重症までの憂うつ症を有する患者は、認知機能のスコアとは無関係に憂うつ症グループに分類された。神経及びコミュニケーション障害並びに脳卒中の国立協会とアルツハイマー病及び関連疾患協会のアルツハイマー病の可能性に対する基準を満たす患者は認知症グループに分類され、一般的な認知機能(CDR 0)を有するヒトは対照群に分類された。基礎嗅覚機能は、韓国型嗅覚検査(Korean version of the Sniffing stick test;KVSS)を用いて評価した。
鼻腔組織検査は、ソウル大学病院耳鼻咽喉科において行われた。2%のリドカイン及び0.1%のエピネフリンの混合物で湿らされた綿ガーゼが血管収縮及び局所麻酔に対してひび割れた隙間に挿入された。組織検査は、内視鏡案内に従い熟練した耳鼻咽喉科専門医により行われた。組織サンプルは、前方鼻中隔(anterior nasal septum)から収集された。小さなキュレット又は小さなピンセットを用いて、2つ又は3つの2mmの組織ブロックを鼻孔から回収した。鼻腔のパッキングは、出血を制御するために組織検査を行ってから10分間行われた。被験者は、15分〜10分間臨床的に観察され、全ての患者は、基礎嗅覚機能に対する評価のための組織検査前にKVSSを受けた。
トータルRNAは、Trizol(インビトロジェン社製、USA)を用いて鼻の粘膜組織から分離し、miRNAは、Ambion mirVana isolationキットを用いて分離した。RT−PCRは、mirVana qRT−PCR miRNA detectionキット及びmiR−206(TM:000510)andU6(TM:001973)snRNA(アプライドバイオシステムズ社製、USA)に対するプライマーセットを用いて行った。
前記実施例1〜3における被験者の基本特性に対する分析結果は、下記表1の通りである。
これらの事項については、表1にまとめて示す。
上記の結果から明らかなように、正常対照群に比べて認知異常があるCDR 0.5及びCDR 1グループが顕著に高いmiR−206の発現レベルを示す。
嗅覚上皮試料のmiRNA RT−PCRの結果を図1に示す。
上記の結果から、嗅覚組織から確認されるmiR−206値が初期アルツハイマー病及び軽度認知障害に顕著な診断効果があることが確認された。
憂うつ症が認知機能に影響を与えるものと知られているため、憂うつ症を有さない患者における認知機能スコア及び相対的なmiR−206レベル間の相関関係を評価した。その結果を図2に示す。
図2のC及びDに示すように、相対的なmiR−206レベルは、BDI−II及びKVSSスコアと相関関係があることは確認されなかった。
Claims (13)
- アルツハイマー病又は軽度認知障害の診断又は予後の分析に必要な情報を提供するために嗅覚組織試料にあるmiR−206の発現を検出する方法を用いてアルツハイマー病又は軽度認知障害の診断又は予後分析マーカーを検出する方法。
- 前記miR−206の発現の検出は、miR−206に特異的に結合するプライマー対、プローブ又はアンチセンスヌクレオチドを用いて行う請求項1に記載のアルツハイマー病又は軽度認知障害の診断又は予後分析マーカーを検出する方法。
- 前記miR−206の発現の検出は、逆転写酵素重合酵素反応、競争的逆転写酵素重合酵素反応、リアルタイム逆転写酵素重合酵素反応、RNase保護分析法、ノーザンブロッティング又はDNAチップにより行われる請求項1に記載のアルツハイマー病又は軽度認知障害の診断又は予後分析マーカーを検出する方法。
- 前記嗅覚組織試料は、嗅覚粘膜試料又は嗅覚上皮試料である請求項1に記載のアルツハイマー病又は軽度認知障害の診断又は予後分析マーカーを検出する方法。
- 前記アルツハイマー病は、初期アルツハイマー病である請求項1に記載のアルツハイマー病又は軽度認知障害の診断又は予後分析マーカーを検出する方法。
- 患者から分離された嗅覚組織試料中でmiR−206の発現レベルを測定するステップと、
前記miR−206の発現レベルを基準レベルと比較するステップと、
を含むアルツハイマー病又は軽度認知障害の診断のための情報の提供方法。 - 前記miR−206の発現レベルを基準レベルと比較して、前記発現が増加すれば、アルツハイマー病又は軽度認知障害であると判定するステップを更に含む請求項6に記載のアルツハイマー病又は軽度認知障害の診断のための情報の提供方法。
- 前記miR−206の発現レベルの測定は、miR−206に特異的に結合するプライマー対、プローブ又はアンチセンスヌクレオチドを用いて行う請求項6に記載のアルツハイマー病又は軽度認知障害の診断のための情報の提供方法。
- 前記miR−206の発現の検出は、逆転写酵素重合酵素反応、競争的逆転写酵素重合酵素反応、リアルタイム逆転写酵素重合酵素反応、RNase保護分析法、ノーザンブロッティング又はDNAチップにより行われる請求項6に記載のアルツハイマー病又は軽度認知障害の診断のための情報の提供方法。
- 前記嗅覚組織試料は、嗅覚粘膜試料又は嗅覚上皮試料である請求項6に記載のアルツハイマー病又は軽度認知障害の診断のための情報の提供方法。
- 前記アルツハイマー病は、初期アルツハイマー病である請求項6に記載のアルツハイマー病又は軽度認知障害の診断のための情報の提供方法。
- miR−206の発現レベルを測定する製剤として、遺伝子に特異的に結合するプライマー対、プローブ又はアンチセンスヌクレオチドを含む初期アルツハイマー病又は軽度認知障害診断用組成物。
- 請求項12に記載の初期アルツハイマー病又は軽度認知障害診断用組成物を含む初期アルツハイマー病又は軽度認知障害診断用キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0068690 | 2015-05-18 | ||
KR1020150068690A KR101734645B1 (ko) | 2015-05-18 | 2015-05-18 | 초기 알츠하이머 병 또는 경도 인지 장애 진단 방법 |
PCT/KR2016/004884 WO2016186360A1 (ko) | 2015-05-18 | 2016-05-10 | 초기 알츠하이머 병 또는 경도 인지 장애 진단 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018515145A true JP2018515145A (ja) | 2018-06-14 |
JP6681976B2 JP6681976B2 (ja) | 2020-04-15 |
Family
ID=57320612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018513247A Active JP6681976B2 (ja) | 2015-05-18 | 2016-05-10 | 初期アルツハイマー病又は軽度認知障害の診断方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20180202997A1 (ja) |
EP (1) | EP3299473B1 (ja) |
JP (1) | JP6681976B2 (ja) |
KR (1) | KR101734645B1 (ja) |
CN (1) | CN107849610B (ja) |
WO (1) | WO2016186360A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021017402A (ja) * | 2019-07-17 | 2021-02-15 | 東海物産株式会社 | 軽度認知障害改善用組成物及びこの組成物を用いた軽度認知障害の改善方法 |
JP2022508304A (ja) * | 2018-09-26 | 2022-01-19 | シャンハイ メンタル ヘルス センター (シャンハイ サイコロジカル カウンセリング トレーニング センター) | Ad誘発mciの診断マーカーとその応用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106544435A (zh) * | 2016-09-30 | 2017-03-29 | 河北医科大学第医院 | 检测miR‑206所需逆转录引物对在制备预测试剂盒中的应用 |
KR102033776B1 (ko) | 2017-10-31 | 2019-10-17 | 가천대학교 산학협력단 | 타우 단백질의 발현수준을 측정하는 제제를 포함하는 알츠하이머 중증도 진단용 조성물 및 이를 이용한 알츠하이머 중증도의 진단방법 |
KR20190112219A (ko) | 2018-03-13 | 2019-10-04 | 전남대학교산학협력단 | 알츠하이머 질병 검출 방법, 알츠하이머 질병 검출 시스템 및 알츠하이머 질병 검출 방법을 수행하는 프로그램이 기록된 컴퓨터로 읽을 수 있는 기록매체 |
EP3807422A1 (en) | 2018-06-15 | 2021-04-21 | Universitat Autònoma de Barcelona | Circulating mirnas as biomarkers for diagnosis of mild cognitive impairment and alzheimer´s disease |
KR102177740B1 (ko) | 2018-12-12 | 2020-11-11 | 재단법인대구경북과학기술원 | 인지 능력 평가 방법, 이의 시스템 및 이를 위한 웨어러블 디바이스 |
KR102473086B1 (ko) * | 2019-03-06 | 2022-12-02 | 한양대학교 에리카산학협력단 | 은 나노갭 쉘을 이용한 알츠하이머병 진단방법 |
KR20220125745A (ko) | 2021-03-04 | 2022-09-14 | 단국대학교 천안캠퍼스 산학협력단 | 후각세포의 진단 및 활성화 장치 |
KR102341233B1 (ko) * | 2021-09-03 | 2021-12-20 | 주식회사 알츠코리아 | 경도인지장애 또는 알츠하이머성 치매 조기 진단을 위한 신규 마이크로 rna 바이오마커 |
CN114438195A (zh) * | 2022-02-28 | 2022-05-06 | 暨南大学 | 阿尔茨海默病检测试剂盒、存储介质及电子设备 |
CN115078570B (zh) * | 2022-05-30 | 2024-05-28 | 郑州大学第一附属医院 | Tau蛋白639位硫氰酸氨基酸修饰在快速质谱法检测阿尔茨海默症中的应用 |
KR20240059132A (ko) | 2022-10-27 | 2024-05-07 | 동의대학교 산학협력단 | 홍화 추출물을 포함하는 후각기능, 기억력 및 인지기능 개선용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120094295A1 (en) * | 2008-11-21 | 2012-04-19 | The Johns Hopkins University | Neurodegenerative disease diagnostic compositions and methods of use |
JP2013542921A (ja) * | 2010-09-13 | 2013-11-28 | エスエヌユー アールアンドディービー ファウンデーション | miRNAをターゲットとした神経変性疾患の治療 |
US20130337466A1 (en) * | 2012-06-14 | 2013-12-19 | Electronics And Telecommunications Research Institute | Method for diagnosing alzheimer's disease using biomaterial |
CN104480106A (zh) * | 2014-10-08 | 2015-04-01 | 河北医科大学第一医院 | 检测轻度认知障碍患者血清/血浆微小rna标志物及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2530157B1 (en) * | 2003-07-31 | 2016-09-28 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of miRNAs |
CA2840196C (en) * | 2011-06-27 | 2022-09-20 | Eisai R&D Management Co., Ltd. | Microrna biomarkers indicative of alzheimer's disease |
KR102031194B1 (ko) * | 2012-06-14 | 2019-10-11 | 한국전자통신연구원 | 베타-아밀로이드의 농도를 측정하는 방법 |
KR101609599B1 (ko) * | 2013-07-26 | 2016-04-07 | 경상대학교 산학협력단 | 항원 검출용 형광 나노입자 및 그를 이용한 알츠하이머 치매의 조기 진단키트 |
-
2015
- 2015-05-18 KR KR1020150068690A patent/KR101734645B1/ko active IP Right Grant
-
2016
- 2016-05-10 JP JP2018513247A patent/JP6681976B2/ja active Active
- 2016-05-10 WO PCT/KR2016/004884 patent/WO2016186360A1/ko active Application Filing
- 2016-05-10 CN CN201680042096.5A patent/CN107849610B/zh active Active
- 2016-05-10 EP EP16796687.8A patent/EP3299473B1/en active Active
- 2016-05-10 US US15/575,804 patent/US20180202997A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120094295A1 (en) * | 2008-11-21 | 2012-04-19 | The Johns Hopkins University | Neurodegenerative disease diagnostic compositions and methods of use |
JP2013542921A (ja) * | 2010-09-13 | 2013-11-28 | エスエヌユー アールアンドディービー ファウンデーション | miRNAをターゲットとした神経変性疾患の治療 |
US20130337466A1 (en) * | 2012-06-14 | 2013-12-19 | Electronics And Telecommunications Research Institute | Method for diagnosing alzheimer's disease using biomaterial |
CN104480106A (zh) * | 2014-10-08 | 2015-04-01 | 河北医科大学第一医院 | 检测轻度认知障碍患者血清/血浆微小rna标志物及其应用 |
Non-Patent Citations (3)
Title |
---|
ANN NEUROL, vol. 67, no. 4, JPN6018045559, 2010, pages 462 - 469, ISSN: 0003921593 * |
ANN NEUROL, vol. 72, JPN6018045563, 2012, pages 269 - 277, ISSN: 0003921595 * |
EXPERIMENTAL NEUROLOGY, vol. 121, JPN6018045561, 1993, pages 93 - 105, ISSN: 0003921594 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022508304A (ja) * | 2018-09-26 | 2022-01-19 | シャンハイ メンタル ヘルス センター (シャンハイ サイコロジカル カウンセリング トレーニング センター) | Ad誘発mciの診断マーカーとその応用 |
JP7291221B2 (ja) | 2018-09-26 | 2023-06-14 | シャンハイ メンタル ヘルス センター (シャンハイ サイコロジカル カウンセリング トレーニング センター) | Ad誘発mciの診断マーカーとその応用 |
JP2021017402A (ja) * | 2019-07-17 | 2021-02-15 | 東海物産株式会社 | 軽度認知障害改善用組成物及びこの組成物を用いた軽度認知障害の改善方法 |
JP7321017B2 (ja) | 2019-07-17 | 2023-08-04 | 東海物産株式会社 | 機能性食品 |
Also Published As
Publication number | Publication date |
---|---|
EP3299473B1 (en) | 2020-10-21 |
JP6681976B2 (ja) | 2020-04-15 |
CN107849610A (zh) | 2018-03-27 |
US20180202997A1 (en) | 2018-07-19 |
EP3299473A1 (en) | 2018-03-28 |
CN107849610B (zh) | 2022-03-11 |
EP3299473A4 (en) | 2018-10-24 |
KR101734645B1 (ko) | 2017-05-11 |
KR20160135430A (ko) | 2016-11-28 |
WO2016186360A1 (ko) | 2016-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6681976B2 (ja) | 初期アルツハイマー病又は軽度認知障害の診断方法 | |
JP7413455B2 (ja) | 外傷性脳傷害のバイオマーカー | |
CA2957549C (en) | Diagnostic method for distinguishing forms of esophageal eosinophilia | |
JP2023113881A (ja) | 乳がんの検出を補助する方法 | |
WO2018056430A1 (ja) | 気分障害を検出する方法 | |
CN111187827A (zh) | 帕金森病生物标志物及其应用 | |
TWI571514B (zh) | 評估罹患大腸直腸癌風險的方法 | |
WO2019117270A1 (ja) | 頭頸部がんの検出を補助する方法 | |
JP2019187413A (ja) | ループス腎炎の検出またはそのリスクを予測する方法およびその応用 | |
Zirnheld et al. | Distinguishing mild cognitive impairment from Alzheimer’s disease by increased expression of key circulating microRNAs | |
US20220325355A1 (en) | Method for diagnosing breast cancer | |
JP7394441B2 (ja) | 脳腫瘍を検査する方法 | |
US20220380850A1 (en) | Salivary biomarkers of brain injury | |
CN114746551A (zh) | 大肠癌诊断用标志物、辅助大肠癌的诊断的方法、收集数据以用于大肠癌诊断的方法、大肠癌的诊断试剂盒、大肠癌治疗药物、大肠癌的治疗方法、大肠癌的诊断方法 | |
US11655507B2 (en) | Method for diagnosing Parkinson's disease using nasal mucus, composition therefore, and kit comprising the same | |
TWI626314B (zh) | 評估罹患大腸直腸癌風險的方法 | |
JP2013138637A (ja) | 疾患関連マイクロrnaとその利用 | |
WO2022019326A1 (ja) | 脳腫瘍の検出を補助する方法 | |
JP2013000067A (ja) | 膀胱ガン診断用組成物及び方法 | |
KR20190015670A (ko) | 미병 판별용 마커 | |
RU2771757C2 (ru) | Биомаркеры травматического повреждения головного мозга | |
JP2018033352A (ja) | 心理的ストレスの検出用キット又はデバイス及び心理的ストレスの検出方法 | |
JP2007228878A (ja) | 慢性疲労症候群の診断方法 | |
WO2021044385A1 (en) | Diagnostic and prognostic liquid biopsy biomarkers for asthma | |
JP2022134127A (ja) | アトピー性皮膚炎による皮膚痒みの症度悪化の検出方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181121 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190425 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190522 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190930 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20191009 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200303 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200317 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200324 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6681976 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |